The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) activators may be beneficial in heart failure due to their metabolic and antihypertrophic effects, but these agents can cause oedema. We hypothesized that, on balance, the PPARgamma activator rosiglitazone would be beneficial in...
| প্রধান লেখক: | , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
2003
|
| _version_ | 1826292387600662528 |
|---|---|
| author | Lygate, C Hulbert, K Monfared, M Cole, M Clarke, K Neubauer, S |
| author_facet | Lygate, C Hulbert, K Monfared, M Cole, M Clarke, K Neubauer, S |
| author_sort | Lygate, C |
| collection | OXFORD |
| description | OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) activators may be beneficial in heart failure due to their metabolic and antihypertrophic effects, but these agents can cause oedema. We hypothesized that, on balance, the PPARgamma activator rosiglitazone would be beneficial in heart failure post-myocardial infarction. METHODS AND RESULTS: Rosiglitazone (3 mg/kg/day p.o.) given to male Wistar rats for 14 days, caused a 31% increase in left ventricular (LV) dP/dt(max) (P<0.05 vs. placebo). A separate group of rats was subjected to sham (SH) or coronary artery ligation and randomised to: untreated (UT); rosiglitazone 3 mg/kg/day (R); captopril, 2 g/l in drinking water (C); captopril+rosiglitazone (C+R). Mean LV infarct sizes were similar for all groups at 40+/-2%. After 8 weeks, echocardiographic ejection fractions were 82+/-3, 40+/-3, 50+/-2*, 49+/-2, 50+/-3% for SH, UT, R, C and C+R groups, respectively (*P<0.05 vs. UT). Captopril prevented LV dilatation, but rosiglitazone did not. In vivo hemodynamics showed that only UT had significantly elevated LV end-diastolic pressures and reduced +dP/dt(max), with R partially, and C and C+R almost completely preventing the increase in LVEDP. Captopril, but not rosiglitazone, significantly reduced LV hypertrophy [LV/bw; 1.97+/-0.09 (SH), 2.15+/-0.04 (UT), 2.10+/-0.05 (R), 1.81+/-0.04* (C), 1.88+/-0.07 (C+R); *(P<0.05 vs. UT)]. Rosiglitazone increased 8-week mortality, which was 26% for R and 19% for C+R compared with 0% for UT and C (P=0.03 vs. UT). CONCLUSIONS: Rosiglitazone did not modulate LV remodeling, but was associated with increased mortality post-myocardial infarction (MI) in rats. The mechanisms require further study, but these results caution against use of PPARgamma activators in post-MI heart failure in non-diabetics. |
| first_indexed | 2024-03-07T03:13:54Z |
| format | Journal article |
| id | oxford-uuid:b52343fa-ea2e-40f1-90e5-731a2eaa92b5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:13:54Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:b52343fa-ea2e-40f1-90e5-731a2eaa92b52022-03-27T04:31:16ZThe PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b52343fa-ea2e-40f1-90e5-731a2eaa92b5EnglishSymplectic Elements at Oxford2003Lygate, CHulbert, KMonfared, MCole, MClarke, KNeubauer, SOBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) activators may be beneficial in heart failure due to their metabolic and antihypertrophic effects, but these agents can cause oedema. We hypothesized that, on balance, the PPARgamma activator rosiglitazone would be beneficial in heart failure post-myocardial infarction. METHODS AND RESULTS: Rosiglitazone (3 mg/kg/day p.o.) given to male Wistar rats for 14 days, caused a 31% increase in left ventricular (LV) dP/dt(max) (P<0.05 vs. placebo). A separate group of rats was subjected to sham (SH) or coronary artery ligation and randomised to: untreated (UT); rosiglitazone 3 mg/kg/day (R); captopril, 2 g/l in drinking water (C); captopril+rosiglitazone (C+R). Mean LV infarct sizes were similar for all groups at 40+/-2%. After 8 weeks, echocardiographic ejection fractions were 82+/-3, 40+/-3, 50+/-2*, 49+/-2, 50+/-3% for SH, UT, R, C and C+R groups, respectively (*P<0.05 vs. UT). Captopril prevented LV dilatation, but rosiglitazone did not. In vivo hemodynamics showed that only UT had significantly elevated LV end-diastolic pressures and reduced +dP/dt(max), with R partially, and C and C+R almost completely preventing the increase in LVEDP. Captopril, but not rosiglitazone, significantly reduced LV hypertrophy [LV/bw; 1.97+/-0.09 (SH), 2.15+/-0.04 (UT), 2.10+/-0.05 (R), 1.81+/-0.04* (C), 1.88+/-0.07 (C+R); *(P<0.05 vs. UT)]. Rosiglitazone increased 8-week mortality, which was 26% for R and 19% for C+R compared with 0% for UT and C (P=0.03 vs. UT). CONCLUSIONS: Rosiglitazone did not modulate LV remodeling, but was associated with increased mortality post-myocardial infarction (MI) in rats. The mechanisms require further study, but these results caution against use of PPARgamma activators in post-MI heart failure in non-diabetics. |
| spellingShingle | Lygate, C Hulbert, K Monfared, M Cole, M Clarke, K Neubauer, S The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title | The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title_full | The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title_fullStr | The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title_full_unstemmed | The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title_short | The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. |
| title_sort | ppargamma activator rosiglitazone does not alter remodeling but increases mortality in rats post myocardial infarction |
| work_keys_str_mv | AT lygatec theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT hulbertk theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT monfaredm theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT colem theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT clarkek theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT neubauers theppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT lygatec ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT hulbertk ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT monfaredm ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT colem ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT clarkek ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction AT neubauers ppargammaactivatorrosiglitazonedoesnotalterremodelingbutincreasesmortalityinratspostmyocardialinfarction |